By Thomas
Escritt , Stephanie Nebehay
BERLIN/GENEVA (Reuters) - Germany, France and Italy said on
Monday they would suspend AstraZeneca COVID-19 shots after several countries
reported possible serious side-effects, but the World Health Organization (WHO)
said there was no proven link and people should not panic.
Still, the decision by the European
Union’s three biggest countries to put inoculations with the AstraZeneca shot
on hold threw the already struggling vaccination campaign in the 27-nation EU
into disarray.
Denmark and Norway stopped giving
the shot last week after reporting isolated cases of bleeding, blood clots and
a low platelet count. Iceland and Bulgaria followed suit and Ireland and the
Netherlands announced suspensions on Sunday.
Spain will stop using the vaccine
for at least 15 days, Cadena Ser radio reported, citing unnamed sources.
The top WHO scientist reiterated on
Monday that there have been no documented deaths linked to COVID-19 vaccines.
“We do not want people to panic,” Soumya
Swaminathan said on a virtual media briefing, adding there has been no
association, so far, pinpointed between so-called “thromboembolic events”
reported in some countries and COVID-19 shots.
WHO chief Tedros Adhanom Ghebreyesus
said an advisory committee meeting on AstraZeneca would be held on Tuesday. EU
medicines regulator EMA will also convene this week to assess the information
gathered into whether the AstraZeneca shot contributed to thromboembolic events
in those inoculated.
The moves by some of Europe’s
largest and most populous countries will deepen concerns about the slow rollout
of vaccines in the region, which has been plagued by shortages due to problems
producing vaccines, including AstraZeneca’s.
Germany warned last week it was
facing a third wave of infections, Italy is intensifying lockdowns and
hospitals in the Paris region are close to being overloaded.
German Health Minister Jens Spahn
said that although the risk of blood clots was low, it could not be ruled out.
More
https://www.reuters.com/article/us-health-coronavirus/germany-italy-france-suspend-astrazeneca-shots-amid-safety-fears-disrupting-eu-vaccinations-idUSKBN2B722U?il=0
New data suggests mRNA COVID-19
vaccines prevent infection
By Rich Haridy March 14, 2021
In
a stunning demonstration of human endeavor, less than one year after a new
virus swept across the world triggering a pandemic, we developed several
effective vaccines that protect those inoculated from hospitalization and
death. However, one key question not answered by rigorous clinical trials last
year was whether the vaccines prevent asymptomatic infection, and onward
transmission.
While
it was clear the vaccines could dramatically reduce rates of death from
COVID-19, it was unclear whether they could prevent mild, or even asymptomatic
infections. Now, as millions have been vaccinated around the world, researchers
are getting some promising early indications that mRNA vaccines in particular
may successfully prevent SARS-CoV-2 infection and subsequent transmission.
Over
100 million Americans have received at least one dose of a mRNA
COVID-19 vaccine (either from Pfizer or Moderna). A new Mayo Clinic-led study,
published in the journal Clinical Infectious Diseases , looked at
retrospective data from nearly 40,000 subjects who took a routine pre-operative
COVID-19 test over the past couple of months. About 3,000 of those subjects had
received at least one dose of an mRNA vaccine more than 10 days before the
COVID-19 test.
“Among
individuals who had received a single dose of vaccine [more than] 10 days prior
to their pre-procedure test, we observed a 72 percent reduction in the risk of
a positive molecular screening test,” the researchers report in the study.
“After adjustment for multiple potential confounding factors, we observed an
80-percent reduction in the risk of a positive molecular screening test among
test performed in persons who had received two doses of vaccine, compared to
those who were not vaccinated.”
These findings promisingly echo several other studies
appearing on pre-print journal servers in recent weeks. A UK investigation tracking healthcare workers in the weeks
following a single dose of the Pfizer mRNA vaccine found a 75-percent reduction
in asymptomatic cases compared to a matched unvaccinated cohort.
Researchers have been closely studying case numbers in
Israel, as that country is leading the world in mass vaccinations. Early
indications are again suggesting asymptomatic infections may drop by as
much as 75 percent two weeks after one dose of the Pfizer vaccine.
In mid-February Anthony Fauci noted during a White House
COVID-19 briefing that preliminary data looking at the first wave of
vaccinations is beginning to suggest mRNA vaccines don’t just prevent severe
disease, but also prevent infection.
"The looming question is, if the person who's been
vaccinated gets infected, does that person have the capability to transmit it
to another person," said Fauci . "Some studies are pointing in a very
favorable direction."
Another major clue these early mRNA vaccines can prevent
onward transmission of the virus are preliminary studies tracking reductions to
overall viral loads in vaccinated subjects who do eventually become infected
with SARS-CoV-2. One study , still in preprint and not yet peer-reviewed,
found viral load to be “four-fold” lower in subjects infected 12 to 28 days
after one dose of the Pfizer vaccine.
A Lancet study looking at transmission of the virus in
Spain confidently noted a correlation between viral load and increased
transmission. Fauci suggests this indicates a person is much less infectious
when they present with a lower viral load.
More
https://newatlas.com/health-wellbeing/mrna-coronavirus-vaccine-prevent-infection-transmission/
Better Covid Vaccines Are Coming,
WHO’s Chief Scientist Says
By Jason Gale 15 March 2021, 10:08 GMT
·
As many as eight new vaccines might be ready by
end of 2021
·
Next crop of vaccines will use alternative
delivery systems
New Covid-19 vaccines, including ones that don’t require
needles and can be stored at room temperature, may be ready for use later this
year or next year, the World Health Organization ’s top scientist said.
Six-to-eight new immunizations may complete clinical studies
and undergo regulatory review by the end of the year, Soumya Swaminathan, the
Geneva-based agency’s chief scientist, said in an interview Saturday.
New vaccines will add to the 10 already shown to work
within a year of Covid-19 being declared a pandemic. The world needs more
immunizations, especially as the virus’s continuous circulation spawns
dangerous new variants and drugmakers struggle
to meet orders . Only 122
countries have started immunizing people, according to data collected by
Bloomberg.
“We’re thrilled with the vaccines that we have,” said
Swaminathan, an Indian pediatrician best known for her
research on tuberculosis and HIV. But “we can improve further,” she said. “I
think, well into 2022, we’re going to see the emergence of improved vaccines.”
The current crop of experimental vaccines use alternative
technologies and delivery systems, and include more single-shot inoculations,
and vaccines that are administered orally, via a nasal spray, and through the
skin using a type of patch . These could bring immunizations that are
better suited to specific groups, such as pregnant women, according to
Swaminathan.
More than
80 candidate vaccines are being studied in people, though some are still in
the early stages of testing and may not be successful. Companies with Covid-19
vaccines already in use have also begun testing updated versions designed to
thwart variants
of the coronavirus that have emerged in recent months.
“We need to continue to support the research and
development of more vaccine candidates, especially as the need for ongoing
booster immunization of populations is still not very clear at this point,”
Swaminathan said. “So we need to be prepared for that in the future.”
The WHO’s strategic advisory group of experts on
immunization is reviewing whether people who have been infected with SARS-CoV-2
need to have two doses of vaccine. Some research indicates that a natural
infection works to prime the immune response to SARS-CoV-2, much as a first
dose would, making a second injection unnecessary.
More
https://www.bloomberg.com/news/articles/2021-03-15/better-covid-vaccines-are-coming-who-s-chief-scientist-says?srnd=premium-europe
This
subscription grants access to the locked content of Spectator.sk and SME.sk for
only one person through a maximum of three different devices or browsers.
To
continue reading the article on this device, please update the list of devices
in the profile settings.
Administer
devices
You can
read everything about device
settings here .
The rest of
this article is premium content at Spectator.sk
Subscribe now
for full access
Subscription
for 4 weeks
4 €
Buy
Subscription
for 1 years
39,90 €
Buy
Subscription
for 2 years
69,90 €
Buy
I already have
subscription - Sign
in
Subscription
provides you with:
Immediate access to all
locked articles (premium content) on Spectator.sk Special weekly news summary +
an audio recording with a weekly news summary to listen to at your
convenience (received on a weekly basis directly to your e-mail) PDF version of the latest
issue of our newspaper, The Slovak Spectator, emailed directly to you Access to all premium content
on Sme.sk and Korzar.sk
Next, some vaccine links
kindly sent along from a LIR reader in Canada. The links come from a most
informative update from Stanford Hospital in California.
World
Health Organization - Landscape of COVID-19 candidate vaccines . https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
NY
Times Coronavirus Vaccine Tracker . https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
Stanford
Website . https://racetoacure.stanford.edu/clinical-trials/132
Regulatory
Focus COVID-19 vaccine tracker . https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
Some other useful Covid links.
Johns Hopkins Coronavirus
resource centre
https://coronavirus.jhu.edu/map.html
Rt Covid-19
https://rt.live/
Centers for Disease Control
Coronavirus
https://www.cdc.gov/coronavirus/2019-ncov/index.html
The Spectator
Covid-19 data tracker (UK)
https://data.spectator.co.uk/city/national
Technology Update.
With events happening
fast in the development of solar power and graphene, I’ve added this section.
Updates as they get reported.
Lightning-fast GigaDrive SSD
boasts read/write speeds of 2,800 MB/s
By Michael Irving March 15, 2021
In
this world overflowing with data and content, external solid state drives are
becoming more and more necessary. Thankfully they’re also getting faster, as
demonstrated by a new SSD called GigaDrive that boasts read and write speeds of
up to 2,800 MB/s thanks to its architecture and Thunderbolt 4- and
USB4-compatible port.
As far as external drives go, the
GigaDrive looks pretty good. It’s nice and small, measuring only 114 x 37 x
12.5 mm and weighing just 74 g (2.6 oz). It comes in 1 TB, 2 TB or 4 TB models,
so there’s plenty of space. And it’s wrapped in a sturdy aluminum shell, which
the company claims is resistant to shocks, water and dust with its IP67 rating.
Apparently that casing also helps it conduct heat and prevent overheating.
But the biggest selling point is its
lightning-fast read and write speeds, clocking in at up to 2,800 MB/s in both
regards. GigaDrive chalks these up to a combination of factors – it’s built on
the NVMe M.2 architecture, and packs a DRAM cache chip that pre-processes where
it will store data in a new transfer.
The drive is also tapping into two
next-generation connections, Thunderbolt 4 and USB4, which both have higher
bandwidth, allowing the faster transfer speeds. While there still aren’t all
that many devices with the new ports, the beauty is that it’s still the same
connector, so it’s compatible with Thunderbolt 3 and most other USB-C devices.
GigaDrive claims it’s the “world’s fastest” external SSD,
which may technically be true but isn’t entirely unheard of either. The average
still seems to hover around 500 MB/s, but existing devices like Samsung’s
Portable X5 have also managed read speeds of 2,800 MB/s. Write speeds are
usually harder to bump up of course, so maybe that specifically is where
GigaDrive is claiming the record.
Either way, the GigaDrive looks like a decent little SSD.
It may not necessarily be as revolutionary as it wants to be, but all of its
features mean it could be a good option for expanding storage on a laptop, desktop,
or your shiny new PlayStation
5 . Or it could plug into a high-end camera and quickly store your photos
and video in the field.
The GigaDrive is currently seeking funding on Indiegogo ,
where it’s already smashed its US$15,000 goal, raising over $115,000 with 40
days remaining on the campaign. Pledges start at $149 for the 1 TB model, $209
for 2 TB and $349 for 4 TB. If all goes to plan, shipping is set to begin in
July 2021.
Check it out in the video below.
https://newatlas.com/computers/gigadrive-ssd-2800mbs-read-write-speeds/
“I
sometimes get the impression that many U.S. media outlets work according to a
principle which was common in the Soviet Union. Back then, people used to joke
that the newspaper Pravda [Truth] had no truth in it, and the Izvestia [News]
paper has no news in it. I get the impression that many U.S. media operate in
the same way.”
Russian Foreign Minister Lavrov. May 2017.
No comments:
Post a Comment